BIIB240712C220000
- 7.10
- -9.79-57.96%
Biogen Newsroom
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease.The drug should be initiated in patients with mild cognitive
Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler
Biogen Price Target Cut to $313.00/Share From $335.00 by Piper
Piper Sandler Maintains Overweight on Biogen, Lowers Price Target to $313
Piper Sandler analyst Christopher Raymond maintains Biogen with a Overweight and lowers the price target from $335 to $313.
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 32.35% Piper Sandler $335 → $313 Maintains Overweight 06/28/2024 24.32% Needham $294 → $294
Express News | Biogen Inc : Piper Sandler Cuts Target Price to $313 From $335
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $313
Piper Sandler analyst Christopher Raymond maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $335 to $313.According to TipRanks data, the analyst has a success rate of 52
Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts polled by Capital IQ.Price: 237.22, Change: +0.42, Percent Change: +0.18
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $311
Morgan Stanley analyst Terence Flynn maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $331 to $311.According to TipRanks data, the analyst has a success rate of 64.8%
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts by Capital IQ.Price: 231.00, Change: -1.75, Percent Change: -0.75
Biogen, Eisai Say Alzheimer's Drug Leqembi Secures Regulatory Approval in Hong Kong
Biogen (BIIB) and Eisai said Thursday that the Alzheimer's disease drug Leqembi has been approved by Hong Kong's Department of Health.The approval was based on a late-stage trial that met its
Barclays Remains a Hold on Biogen (BIIB)
RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating
Biogen (BIIB) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $200 to $350.Price: 228.20, Change: +0.13, Percent Change: +0.06
Express News | Biogen Inc : RBC Cuts Target Price to $303 From $317
Immunic Appoints Ex Novartis and Biogen Exec as New COO to Lead Vidofludimus Calcium Launch | NASDAQ:IMUX
BMO: Eli Lilly and Co's Alzheimer's drug is expected to generate revenue of $7.1 billion, which is better than Biogen's competitor.
According to BMO reports, eli lilly and co's newly approved Alzheimer's drug donanemab could bring in peak sales of up to $7.1 billion for the company.
Lilly's New Alzheimer's Drug Could Generate $7.1B in Sales: Analyst
Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th